Trial Profile
A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2018
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder; Urination disorders
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 04 Sep 2012 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 21 Jul 2009 New trial record